HIF-1 at the crossroads of hypoxia, inflammation, and cancer

International Journal of Cancer

Volumn 138, Issue 5, 2016, Pages 1058-1066

  Balamurugan, Kuppusamy ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer stem cells; drug resistance; HIF 1; hypoxia; inflammation; microenvironment

Indexed keywords

DOXORUBICIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1; REACTIVE OXYGEN METABOLITE;

CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; IMMUNE RESPONSE; INFLAMMATION; METABOLISM; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; CELL HYPOXIA; NEOPLASMS; PHYSIOLOGY;

ANIMALS; CELL HYPOXIA; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; NEOPLASMS; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES; TUMOR MICROENVIRONMENT;

EID: 84955657303     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29519     Document Type: Review

References (154)

1. Lokmic Z, Musyoka J, Hewitson TD, et al., Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int Rev Cell Mol Biol 2012; 296: 139-85.
2. Hong WX, Hu MS, Esquivel M, et al., The role of hypoxia-inducible factor in wound healing. Adv Wound Care (New Rochelle) 2014; 3: 390-99.
3. Semenza GL,. Oxygen sensing, hypoxia-inducible factors and disease pathophysiology. Annu Rev Pathol 2014; 9: 47-71.
4. Wenger RH, Stiehl DP, Camenisch G,. Integration of oxygen signaling at the consensus HRE. Sci Stke 2005; 306: re12
5. Keith B, Johnson RS, Simon MC,. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011; 12: 9-22.
6. Hara S, Hamada J, Kobayashi C, et al., Expression and characterization of hypoxia-inducible factor (HIF)-3a in human kidney: suppression of HIF-mediated gene expression by HIF-3a. Biochem Biophys Res Commun 2001; 287: 808-13.
7. Maynard MA, Evans AJ, Shi W, et al., Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 2007; 15: 2810-16.
8. Zhang P, Yao Q, Lu L, et al., Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia. Cell Rep 2014; 6: 1110-21.
9. Scholz CC, Taylor CT,. Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol 2013; 13: 646-53.
10. Vaupel P, Mayer A,. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol 2014; 812: 19-24.
11. Zhou J, Schmid T, Schnitzer S, et al., Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21.
12. Zhong H, De Marzo AM, Laughner E, et al., Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-35.
13. Feldser D, Agani F, Iyer NV, et al., Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-18.
14. Lu H, Forbes RA, Verma A,. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-15.
15. Maxwell PH, Wiesener MS, Chang GW, et al., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen dependent proteolysis. Nature 1999; 399: 271-75.
16. Jiang BH, Agani F, Passaniti A, et al., V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
17. Cramer T, Yamanishi Y, Clausen BE, et al., Hif-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-57.
18. Walmsley SR, Print C, Farahi N, et al., Hypoxia-induced neutrophil survival is mediated by hif-1alpha-dependent NF-kB activity. J Exp Med 2005; 201: 105-15.
19. Dang EV, Barbi J, Yang HY, et al., Control of t(h)17/t(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-84.
20. Higashiyama M, Hokari R, Hozumi H, et al., HIF-1 in T cells ameliorated dextran sodium sulfate-induced murine colitis. J Leukoc Biol 2012; 91: 901-9.
21. Jantsch J, Chakravortty D, Turza N, et al., Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 2008; 180: 4697-705.
22. Zampell JC, Yan A, Avraham T, et al., HIF-1α coordinates lymphangiogenesis during wound healing and in response to inflammation. FASEB J 2012; 26: 1027-39.
23. Noman MZ, Desantis G, Janji B, et al., PD-l1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211: 781-90.
24. Shah YM, Ito S, Morimura K, et al., Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 2008; 134: 2036-48.
25. Peyssonnaux C, Cejudo-Martin P, Doedens A, et al., Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol 2007; 178: 7516-9.
26. Mantovani A, Allavena P, Sica A, et al., Cancer-related inflammation. Nature 2008; 454: 436-44.
27. Mamlouk S, Wielockx B,. Hypoxia-inducible factors as key regulators of tumor inflammation. Int J Cancer 2013; 132: 2721-29.
28. Noman MZ, Messai Y, Carré T, et al., Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 2011; 31: 357-77.
29. Semenza GL,. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013; 32: 4057-63.
30. Bruning U, Fitzpatrick SF, Frank T, et al., NFκB and HIF display synergistic behavior during hypoxic inflammation. Cell Mol Life Sci 2012; 69: 1319-29.
31. Hoesel B, Schmid JA,. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86
32. Zong WX, Edelstein LC, Chen C, et al., The prosurvival Bcl-2 homolog Bfl-1/a1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-87.
33. Maxwell PJ, Gallagher R, Seaton A, et al., HIF-1 and NF-kappaB-mediated upregulation of cxcr1 and cxcr2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007; 26: 7333-45.
34. Lavecchia A, Di Giovanni C, Cerchia C,. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert Opin Ther Pat 2014; 24: 383-400.
35. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al., Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009; 1171: 59-76.
36. Jung JE, Lee HG, Cho IH, et al., STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005; 19: 1296-98.
37. Multhoff G, Molls M, Radons J,. Chronic inflammation in cancer development. Front Immunol 2012; 2: 98
38. Paulus MR, Wang L, Hu CJ,. Stat3 and HIF1α cooperatively activate hif1 target genes in MDA-MB-231 and rcc4 cells. Oncogene 2014; 33: 1670-9.
39. Noman MZ, Buart S, Van Pelt J, et al., The cooperative induction of hypoxia-inducible factor-1 alpha and stat3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182: 3510-21.
40. Tamatani T, Azuma M, Ashida Y, et al., Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004; 108: 912-21.
41. Yan HQ, Huang XB, Ke SZ, et al., Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation. Cancer Sci 2014; 105: 1220-7.
42. Yin Z, Zhang Y, Li Y, et al., Prognostic significance of stat3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem 2012; 114: 151-58.
43. Yang C, He L, He P,. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/stat3/bcl-2 signaling pathway. Med Oncol 2015; 32: 352.
44. Zhang C, Yang X, Zhang Q, et al., STAT3 inhibitor nsc74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α. Tumour Biol 2014; 35: 9793-99.
45. Kim SY, Choi YJ, Joung SM, et al., Hypoxic stress up-regulates the expression of toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology 2009; 4: 516-24.
46. Oblak A, Jerala R,. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011;2011: 609579
47. Tewari R, Choudhury SR, Ghosh S, et al., Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl) 2012; 90: 67-80.
48. Zhang JJ, Wu HS, Wang L, et al., Expression and significance of tlr4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010; 21: 2881-88
49. Alfranca A, Gutiérrez MD, Vara A, et al., c-jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 2002; 22: 12 22:
50. Salnikow K, Kluz T, Costa M, et al., The regulation of hypoxic genes by calcium involves c-jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol 2002; 22: 1734-41.
51. Gariboldi MB, Ravizza R, Monti E,. The igfr1 inhibitor NVP-aew541 disrupts a pro- survival and pro-angiogenic IGF-STAT3-hif1 pathway in human glioblastoma cells. Biochem Pharmacol 2013; 80: 455-62. [PMC][10.1016/j.bcp.2010.05.011] [20488164]
52. Mancini M, Gariboldi MB, Taiana E, et al., Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer 2014; 110: 2865-73.
53. Lu J, Tan M, Cai Q,. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 2015; 356: 156-64.
54. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, et al., HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084-101.
55. Christofk HR, Vander Heiden MG, Harris MH, et al., The m2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 2008; 452: 230-3.
56. Luo W, Hu H, Chang R, et al., Pyruvate kinase m2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732-44.
57. Dang CV, Kim J-W, Gao P, et al., The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
58. Sun Q, Chen X, Ma J, et al., Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type m2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129-34.
59. Balamurugan K, Wang JM, Tsai HH, et al., The tumour suppressor C/EBPδ inhibits fbxw7 expression and promotes mammary tumour metastasis. EMBO J 2010; 29: 4106-17.
60. Martinez-Outschoorn UE, Lisanti MP, Sotgia F,. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014; 25: 47-60.
61. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al., Evidence for a stromal- epithelial »lactate shuttle» in human tumors: mct4 is a marker of oxidative stress in cancer- associated fibroblasts. Cell Cycle 2011; 10: 1772-83.
62. Ullah MS, Davies AJ, Halestrap AP,. The plasma membrane lactate transporter mct4, but not mct1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281: 9030-7.
63. Palomäki S, Pietilä M, Laitinen S, et al., HIF-1α is upregulated in human mesenchymal stem cells. Stem Cells 2013; 31: 1902-9.
64. Parks SK, Chiche J, Pouysségur J,. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013; 13: 611-23.
65. Shimoda LA, Fallon M, Pisarcik S, et al., HIF-1 regulates hypoxic induction of nhe1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 2006; 29: L941-9.
66. Svastová E, Hulíková A, Rafajová M, et al., Hypoxia activates the capacity of tumor- associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-45.
67. Sanità P, Capulli M, Teti A, et al., Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer 2014; 14: 154
68. Yamagata M, Hasuda K, Stamato T, et al., The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77: 1726-31.
69. de Nadai TR, de Nadai MN, Albuquerque AA, et al., Metabolic acidosis treatment as part of a strategy to curb inflammation. Int J Inflam 2013; 2013: 601424
70. Wojtkowiak JW, Verduzco D, Schramm KJ, et al., Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011; 8: 2032-8.
71. Garedew A, Henderson SO, Moncada S,. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ 2010; 17: 1540-50.
72. Krawczyk CM, Holowka T, Sun J, et al., Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010; 115: 4742-49.
73. Shi LZ, Wang R, Huang G, et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of th17 and treg cells. J Exp Med 2011; 208: 1367-76.
74. Cheng SC, Quintin J, Cramer RA, et al., mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014; 345: 1250684
75. Junttila MR, de Sauvage FJ,. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501: 346-54.
76. Chouaib S, Kieda C, Benlalam H,. 7 6, aet. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010; 30: 529-45.
77. Forsythe JA, Jiang BH, Iyer NV, et al., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
78. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al., Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
79. Simon MP, Tournaire R, Pouyssegur J,. The angiopoietin-2 gene of endothelial cells is up- regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008; 217: 809-18.
80. Schito L, Rey S, Tafani M, et al., Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 2012; 109: e2707-16.
81. Zhang H, Wong CC, Wei H, et al., HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012; 31: 1757-70.
82. Johnson BF, Clay TM, Hobeika AC, et al., Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007; 7: 449-60.
83. Woo SR, Corrales L, Gajewski TF,. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33: 15.1-15.30.
84. Solito S, Pinton L, Damuzzo V, et al., Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol Invest 2012; 41: 722-37.
85. Medrek C, Pontén F, Jirström K, et al., The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012; 12: 306 [PMC][10.1186/1471-2407-12-306 ] [22824040]
86. Werno C, Menrad H, Weigert A, et al., Knockout of HIF-1α in tumor-associated macrophages enhances m2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis 2010; 31: 1863-72.
87. Tsutsui S, Yasuda K, Suzuki K, et al., Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005; 14: 425-31.
88. Coffelt SB, Tal AO, Scholz A, et al., Angiopoietin-2 regulates gene expression in TIE2- expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70: 5270-80.
89. Du R, Lu KV, Petritsch C, et al., HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-20.
90. Chen WT, Hung WC, Kang WY, et al., Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis. APMIS 2009; 117: 176-84.
91. Hernandez L, Smirnova T, Kedrin D, et al., The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and cxcl12. Cancer Res 2009; 69: 3221-7.
92. Chaturvedi P, Gilkes DM, Takano N, et al., Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci USA 2014; 111: E2120-9.
93. Corzo CA, Condamine T, Lu L, et al., HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-53.
94. Chafe SC, Lou Y, Sceneay J, et al., Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. Cancer Res 2015; 75: 1-13.
95. Hingorani SR, Palculict TB, Izzo J, et al., Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 2013; 73: 3235-47.
96. Gilkes DM, Bajpai S, Chaturvedi P, et al., Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing p4ha1, p4ha2, and plod2 expression in fibroblasts. J Biol Chem 2013; 288: 10819-29.
97. Gilkes DM, Bajpai S, Wong CC, et al., Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res 2013; 11: 456-66.
98. Poggi A, Musso A, Dapino I, et al., Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 2014; 159: 55-72.
99. Lamouille S, Xu J, Derynck R,. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-96.
100. Gheldof A, Berx G,. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci 2013; 116: 317-36.
101. Ikenouchi J, Matsuda M, Furuse M, et al., Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by snail. J Cell Sci 2003; 116: 1959-1967.
102. Krishnamachary B, Zagzag D, Nagasawa H, et al., Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-lindau tumor suppressor-null renal cell carcinoma mediated by tcf3, ZFHX1A, and ZFHX1B. Cancer Res 2006; 66: 2725-31.
103. Yang MH, Wu MZ, Chiou SH, et al., Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
104. Zhang J, Cheng Q, Zhou Y, et al., Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol 2013; 49: 1043-50.
105. Zhu GH, Huang C, Feng ZZ, et al., Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Dig Dis Sci 2013; 58: 3503-15.
106. Giannoni E, Bianchini F, Calorini L, et al., Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 2011; 14: 2361-71.
107. Fiaschi T, Giannoni E, Taddei ML, et al., Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013; 12: 1791-801.
108. Kim HJ, Park JW, Cho YS, et al., Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta 2013; 1832: 183-94.
109. Chuang MJ, Sun KH, Tang SJ, et al., Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008; 99: 905-13.
110. McMahon S, Charbonneau M, Grandmont S, et al., Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of phd2 expression. J Biol Chem 2006; 281: 24171-81.
111. Nishi H, Nakada T, Hokamura M, et al., Hypoxia-inducible factor-1 transactivates transforming growth factor-beta3 in trophoblast. Endocrinology 2004; 145: 4113-8. 1.
112. Copple BL,. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int 2010; 30: 669-82.
113. Lin G, Gai R, Chen Z, et al., The dual PI3K/mTOR inhibitor NVP-bez235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1. Eur J Pharmacol 2014; 729: 45-53.
114. Kato S, Hayakawa Y, Sakurai H, et al., Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of wnt3 and WNT5B. Cancer Sci 2014; 105: 281-89.
115. Jiang YG, Luo Y, He DL, et al., Role of wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor- 1alpha. Int J Urol 2007; 14: 1034-39.
116. Zhang Q, Bai X, Chen W, et al., Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. Carcinogenesis 2013; 34: 962-73.
117. Cheng ZX, Sun B, Wang SJ, et al., Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. PLoS One 2011; 6: e23752
118. Sahlgren C, Gustafsson MV, Jin S, et al., Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008; 105: 6392-7.
119. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
120. Singh AK, Arya RK, Maheshwari S, et al., Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer 2015; 136: 1991-2000.
121. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-37.
122. Lapidot T, Sirard C, Vormoor J, et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-48.
123. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-88.
124. Cojoc M, Mäbert K, Muders MH, et al., A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol 2014; 31: 16-27.
125. Philip B, Ito K, Moreno- SR, et al., HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013; 34: 1699-707.
126. Lan L, Luo Y, Cui D, et al., Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol 2013; 43: 113-20.
127. Luo Y, Cui X, Zhao J, et al., Cells susceptible to epithelial-mesenchymal transition are enriched in stem-like side population cells from prostate cancer. Oncol Rep 2014; 31: 874-84.
128. Mimeault M, Batra SK,. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013; 17: 30-54.
129. Qiang L, Wu T, Zhang HW, et al., HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating notch signaling pathway. Cell Death Differ 2012; 19: 284-94.
130. Zhu H, Wang D, Zhang L, et al., Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of cd133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep 2014; 32: 935-42.
131. Miao ZF, Zhao TT, Wang ZN, et al., Influence of different hypoxia models on metastatic potential of SGC-7901 gastric cancer cells. Tumour Biol 2014; 35: 6801-8.
132. Bhaskara VK, Mohanam I, Rao JS, et al., Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One 2012; 7: e30905
133. Schwab LP, Peacock DL, Majumdar D, et al., Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 2012; 14: r6
134. Wang Y, Liu Y, Malek SN, et al., Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8: 399-411.
135. Yeung TM, Gandhi SC, Bodmer WF,. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci USA 2011; 108: 4382-87.
136. Giannoni E, Parri M, Chiarugi P,. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 2012; 16: 1248-63.
137. 2 sensing. J Biol Chem 2000; 275: 25130-38.
138. Callapina M, Zhou J, Schmid T, et al., NO restores HIF-1α hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med 2005; 39: 925-36.
139. Kirschmann DA, Seftor EA, Fong SF, et al., A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002; 62: 4478-83.
140. Nishi K, Oda T, Takabuchi S, et al., LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal 2008; 10: 983-95.
141. Cho KH, Choi MJ, Jeong KJ, et al., A ROS/stat3/HIF-1α signaling cascade mediates EGF-induced twist1 expression and prostate cancer cell invasion. Prostate 2014; 74: 528-36.
142. Calvani M, Comito G, Giannoni E, et al., Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species. PLoS One 2012; 7: e38388
143. Seebacher NA, Richardson DR, Jansson PJ,. Glucose Modulation Induces Reactive Oxygen Species and Increases Pgp-Mediated Multidrug-Resistance to Chemotherapeutics. Br J Pharmacol 2015. doi: 10.1111/bph.13079.
144. Shimojo Y, Akimoto M, Hisanaga T, et al., Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis 2013; 30: 143-54.
145. Rohwer N, Cramer T,. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14: 191-201.
146. Liang D, Kong X, Sang N,. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006; 5: 2430 5:
147. Conley S, Gheordunescu E, Kakarala P, et al., Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. USA 2012; 109: 2784-89. [PMC][10.1073/pnas.1018866109] [22308314]
148. Wang R, Cheng L, Xia J, et al., Gemcitabine resistance is associated with epithelial- mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Curr Cancer Drug Targets 2014; 14: 407-17.
149. Miyazaki S, Kikuchi H, Iino I, et al., Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer 2014; 135: 295-307.
150. Kung AL, Wang S, Klco JM, et al., Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-40.
151. Rapisarda A, Zalek J, Hollingshead M, et al., Schedule-dependent inhibition of hypoxia- inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64: 6845-8.
152. Zhang H, Qian DZ, Tan YS, et al., Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-86.
153. Lao BB, Grishagin I, Mesallati H, et al., In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci USA 2014; 111: 7531-36.
154. Shay JE, Imtiyaz HZ, Sivanand S, et al., Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis 2014; 35: 1067-77.